ArticleJournal of neuro-oncology2026
Integrated serum and tissue NMR metabolomics with correlation analysis reveals metabolic alterations in gliomas.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGliomas exhibit an inherent metabolic reprogramming driven by the tumor heterogeneity and bioenergetic requirements. The resulting perturbations in systemic circulation can be captured through serum metabolomics, while tissue metabolomics can help decode the tumor-intrinsic changes. Integrating these two can reveal co-ordinated changes, potentially aiding biomarker discovery. Our pilot study aims to investigate the metabolic alterations in gliomas by combining and correlating serum and tissue metabolomics in a North Indian cohort.
methodSerum (n = 50) samples from human glioma patients and healthy controls and tissue samples (n = 34) from patients were collected and analysed after acquisition of 1D-
resultsEight metabolites were statistically significant in differentiating control from disease group in serum samples. Five metabolites were significant in ANOVA from different tissue grades out of which glycine, histamine and pyruvate displayed a gradual trend with the progression of grades.
conclusionSerum and tissue metabolomics were able to capture disease specific perturbation in the metabolome. Integrated analysis provides more comprehensive understanding of glioma biology and may help in non-invasive assessment and grade discrimination.
Indexed as
Identifiers
42348073What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.